ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 346

Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis

Sizheng Zhao1,2, Barbara Hauser3, Micaela Visconti3, Philip L. Riches3, Stuart H. Ralston3 and Nicola Goodson1,2, 1Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 2Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 3Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: axial spondyloarthritis, bone metabolism, fractures, osteoporosis and osteoprotegerin

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as a decoy receptor for RANK-L and inhibits osteoclastogenesis. Previous work has suggested that antibodies to OPG (OPG-Ab) occur more commonly in patients with autoimmune disease and may be associated with increased bone turnover. The aim of this study was to determine whether OPG-Ab are associated with bone health in axSpA.

Methods: Patients with a clinical diagnosis of axSpA were recruited from routine outpatient clinics at two centres in the United Kingdom between 2011-2015. Patient demographics and disease characteristics and fracture history were recorded. All had BMD assessment using anteroposterior dual-energy X-ray absorptiometry (AP-DEXA). Serum levels of OPG-Ab were measured from each patient in triplicate using an in-house ELISA (intra-assay coefficient of variation 10.4%). Patients were considered to be positive for OPG-Ab if values were ≥13units (3 standard deviations above the mean in 100 healthy controls). Associations between OPG-Ab and disease characteristics were assessed by univariate logistic regression. Association with BMD and fractures were assessed by linear and logistic regression, respectively (adjusted for age, gender, duration since diagnosis, BMI and study centre).

Results: We studied 134 patients of whom 75% were male. The mean age was 47 (SD±15) years, and 71% were HLA-B27 positive. 16 patients tested positive for OPG-Ab (11.9%). Presence of OPG-Ab was not associated with patient demographics, axSpA disease characteristics/activity, but was associated with increasing years of disease duration (OR 1.04; 95%CI 1.00, 1.07; P=0.045). OPG-Ab positive patients had reduced hip (but not spinal) BMD and increased history of fracture (Table 1). OPG-Ab positivity was associated with reduced t-score at the hip (ß=-0.83; 95%CI -1.47,-0.18; P=0.012) and increased odds of any fracture (ORadj4.63; 95%CI 1.36, 15.8; P=0.014).

Conclusion: This cross-sectional study demonstrates that the prevalence of OPG-Ab is much higher in axSpA than the healthy population (population prevalence 1%, P<0.001). In axSpA presence of OPG-Ab was strongly and independently associated with hip BMD and history of fractures. This raises the possibility that OPG-Ab may contribute to the bone loss and increased fracture risk observed in axSpA. Spinal BMD is not accurately assessed by AP-DEXA due to presence of syndesmophytes, and it is likely that vertebral BMD will be reduced to a similar extent at the spine. Future studies should utilize lateral spinal DEXAs. OPG-Ab positive axSpA patients may warrant more rigorous bone protection and BMD monitoring.

Table 1 Difference in bone mineral density (BMD) between OPGa positive and negative patients.

 

Total

Positive

(n=16)

Negative

(n=118)

P-value

Height (cm)

171 ± 9.8

166 ± 8

171 ± 10.0

0.064

Weight (kg)

81.8 ± 17.3

82.6 ± 15.2

81.7 ± 17.6

0.860

BMI (kg/m2)

28.0 ± 5.4

29.9 ± 5.4

27.7 ± 5.3

0.130

Spine BMD (g/cm2) n=114

1.161 ± 0.224

1.244 ± 0.230

1.149 ± 0.221

0.125

Spine T-score n=113

0.027 ± 1.684

0.600 ± 1.650

-0.060 ± 1.681

0.158

Hip BMD (g/cm2) n=106

0.988 ± 0.173

0.890 ± 0.144

1.004 ± 0.173

0.018

Hip T-score n=105

-0.449 ± 1.174

-1.167 ± 1.095

-0.329 ± 1.149

0.010

Hip osteopenia

36 (34%)

10 (67%)

26 (29%)

0.007

Hip osteoporosis

4 (4%)

2 (13%)

2 (2%)

0.097

Any fractures

31 (23%)

8 (50%)

23 (19%)

0.007


Disclosure: S. Zhao, None; B. Hauser, None; M. Visconti, None; P. L. Riches, None; S. H. Ralston, None; N. Goodson, None.

To cite this abstract in AMA style:

Zhao S, Hauser B, Visconti M, Riches PL, Ralston SH, Goodson N. Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/autoantibodies-to-osteoprotegerin-are-independently-associated-with-low-hip-bone-mineral-density-and-increased-fractures-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-to-osteoprotegerin-are-independently-associated-with-low-hip-bone-mineral-density-and-increased-fractures-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology